Cancer immunotherapy in special challenging populations: recommendations of the Advisory Committee of Spanish Melanoma Group (GEM)

Cancer immunotherapy based on the use of antibodies targeting the so-called checkpoint inhibitors, such as programmed cell death-1 receptor, its ligand, or CTLA-4, has shown durable clinical benefit and survival improvement in melanoma and other tumors. However, there are some special situations tha...

Descripción completa

Detalles Bibliográficos
Autores principales: Gonzalez-Cao, Maria, Puertolas, Teresa, Riveiro, Mar, Muñoz-Couselo, Eva, Ortiz, Carolina, Paredes, Roger, Podzamczer, Daniel, Manzano, Jose Luis, Molto, Jose, Revollo, Boris, Carrera, Cristina, Mateu, Lourdes, Fancelli, Sara, Espinosa, Enrique, Clotet, Bonaventura, Martinez-Picado, Javier, Cerezuela, Pablo, Soria, Ainara, Marquez-Rodas, Ivan, Mandala, Mario, Berrocal, Alfonso
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2021
Materias:
Position Article and Guidelines
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8009216/
https://www.ncbi.nlm.nih.gov/pubmed/33782108
http://dx.doi.org/10.1136/jitc-2020-001664

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8009216/
https://www.ncbi.nlm.nih.gov/pubmed/33782108
http://dx.doi.org/10.1136/jitc-2020-001664

Ejemplares similares